15 / 34
Data cutoff: February 26, 2016
a
ITT population;
b
Investigator assessment
CI, confidence interval; HR, hazard ratio; ITT, intention to treat; LET, letrozole; PAL,
palbociclib; PBO, placebo; PFS, progression-free survival
Finn RS, et al. Poster presented at ASCO 2017 (Abstract 1039)
PAL + LET
(n=214)
PBO + LET (n=110)
Median (95% CI) PFS, months
19.3 (16.4–22.2) 12.9 (8.4–16.6)
HR (95% CI)
0.63 (0.47–0.85)
P value
<0.005
Time (months)
0
4
8
12
16
20
24
28
32
36
PFS (%)
0
20
40
60
80
100
PAL + LET
PBO + LET
No. at risk
214
184
163
135
114
64
23
4
110
78
66
51
41
24
9
1
0
PBO + LET
Censored
PAL + LET
PFS in Patients with Visceral Disease
Enfermedad Luminal
Agresiva